Collegium Pharma (COLL) Tops Q2 EPS by 5c, misses on revenue

Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of $1.26, $0.05 better than the analyst estimate of $1.21. Revenue for the quarter came in at $135.5 million versus the consensus estimate of $138.41 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• BIG3 Basketball to go public via Graf Global merger at $290 million
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital